Status:
COMPLETED
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Lead Sponsor:
Biogen
Collaborating Sponsors:
Elan Pharmaceuticals
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substanc...
Detailed Description
The primary objective of this study is to determine the effects of various therapies (immunomodulatory as well as immunosuppressive) on ATP levels in CD4+ cells and to determine whether the "ImmuKnow®...
Eligibility Criteria
Inclusion
- Patients must be taking 1 of the following medications for 3 months or more: Cytoxan, Cellcept, Novantrone Betaseron, Rebif, Avonex or Copaxone.
- Patients must be able to provide written informed consent.
Exclusion
- Patients on combination of multiple medications.
- Restricted treatment whereby no use in 50 days prior to enrollment visit is permitted: systemic steroids.
- With educational completion below 8th grade school equivalent or non-fluent in English.
- Any other reason, in the opinion of both the Investigator and/or Sponsor, the patient is determined not suitable for study participation.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00618267
Start Date
March 1 2008
End Date
December 1 2008
Last Update
March 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital - Partners MS Center
Brookline, Massachusetts, United States, 02445